Focused On-demand Library for Anoctamin-5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q75V66

UPID:

ANO5_HUMAN

Alternative names:

Gnathodiaphyseal dysplasia 1 protein; Transmembrane protein 16E

Alternative UPACC:

Q75V66

Background:

Anoctamin-5, also known as Gnathodiaphyseal dysplasia 1 protein or Transmembrane protein 16E, is distinguished by its unique biological role, despite not exhibiting calcium-activated chloride channel (CaCC) activity. This protein's involvement in various diseases underscores its significance in human health.

Therapeutic significance:

Anoctamin-5 is implicated in several diseases, including Gnathodiaphyseal dysplasia, Muscular dystrophy, limb-girdle, autosomal recessive 12, and Miyoshi muscular dystrophy 3. These associations highlight the protein's potential as a target for therapeutic intervention, offering hope for treatments that could alleviate symptoms or perhaps cure these conditions.